tickdelta
tickdelta
Sign in

Tickdelta is free for now. Sign up and get Pro free

← Screener

ABTAbbott Laboratories

Health care · Pharmaceuticals · NYSE

Abbott Laboratories is an Illinois corporation, incorporated in 1900. 10-K, Item 1

ABT quote by TradingView
Employees
115,000
Headquarters
Abbott Park, IL
CEO
Robert B. Ford
Next results
around Jan 21, 2027
Compare with peers → Embed
All key numbers (42, from the latest 10-K and 10-Q) From EDGAR
EPS (ttm)2.69Sales (ttm)48.2BNet income (ttm)4.7BSales growth+5.7%EPS growth-51.3%Sales Q/Q+14.5%
Free cash flow6.8BGross margin56.9%Oper. margin13.8%Net margin9.7%FCF margin14.0%ROE9.2%
ROA4.3%R&D / sales6.6%Dividend2.40Debt/Eq0.61Curr. ratio1.45Cash4.1B
Op. cash flow (ttm)8.9BEBITDA9.5BEBITDA margin21.4%Net debt27.1BQuick ratio1.05Interest cover16.33
ROIC7.6%Payout ratio64.5%Tax rate22.9%Stock pay / sales1.5%Shares out.1.7BShares Y/Y0.0%
Book / share29.46Cash / share2.34Sales / share27.85Asset turnover0.45Inventory turns2.98Days sales out.65
Sales 3Y CAGR+0.5%Sales 5Y CAGR+5.1%EPS 3Y CAGR-1.6%EPS 5Y CAGR+8.3%Employees115,000Sales / employee419K

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

ABT against Health care peers

Ten years, side by side → · All 60 →
GrowthProfitBalanceCleanInsiders
ABTPeer median

Each side 0 to 100, ranked against every company we cover: relative position on reported figures, not a buy score. How

Every dot is one of the 60 companies, the better end on the right. Hover a dot for the company.

Sales growth
+5.7%39th of 60 · median +7.1%
Net margin
9.7%30th of 60 · median 9.6%
Return on equity
9.2%35th of 54 · median 13.1%
Free cash flow margin
14.0%33rd of 56 · median 15.5%
Debt / equity (less is better)
0.6122nd of 49 · median 0.66
ABT and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthGross marginNet marginROEFCF marginDebt / equity
ABT Abbott Laboratories$48.2B +5.7%56.9%9.7%9.2%14.0%0.61
PFE Pfizer$63.6B -1.6%73.4%6.3%4.5%18.5%0.70
BMY Bristol Myers Squibb$50.0B -0.2%69.2%18.5%39.5%18.6%1.86
TMO Thermo Fisher Scientific$47.4B +3.9%-14.9%12.9%16.0%0.79
AMGN Amgen$38.9B +10.0%70.9%24.1%65.4%24.6%3.76
MDT Medtronic$37.5B +8.4%65.0%13.9%10.4%16.3%0.56

From $43.1B of sales to $7.1B of profit

FY2021, from the 10-K income statement
Revenue to Gross profit: $24.5BRevenue to Cost of revenue: $18.5BGross profit to Operating profit: $8.4BGross profit to Operating expenses: $16.1BOperating profit to Net profit: $7.1BOperating profit to Tax & other: $1.4BOperating expenses to R&D: $2.7BOperating expenses to Sales, admin & other: $13.4B Revenue: $43.1B Revenue$43.1B +24% Y/Y Gross profit: $24.5B · 57% margin Gross profit$24.5B57% margin Cost of revenue: $18.5B · 43% of revenue Cost of revenue$18.5B43% of revenue Operating profit: $8.4B · 20% margin Operating profit$8.4B20% margin +57% Y/Y Operating expenses: $16.1B · 37% of revenue Operating expenses$16.1B37% of revenue Net profit: $7.1B · 16% margin Net profit$7.1B16% margin +57% Y/Y Tax & other: $1.4B · 3% of revenue Tax & other$1.4B3% of revenue R&D: $2.7B · 6% of revenue R&D$2.7B6% of revenue Sales, admin & other: $13.4B · 31% of revenue Sales, admin & other$13.4B31% of revenue

Swipe sideways for the whole flow →

From $43.7B of sales to $6.9B of profit

FY2022, from the 10-K income statement and revenue by segment
Medical Devices to Revenue: $14.8BDiagnostic Products to Revenue: $16.5BNutritional Products to Revenue: $7.5BEstablished Pharmaceutical Products to Revenue: $4.9BRevenue to Gross profit: $24.5BRevenue to Cost of revenue: $19.1BGross profit to Operating profit: $8.4BGross profit to Operating expenses: $16.1BOperating profit to Net profit: $6.9BOperating profit to Tax & other: $1.4BOperating expenses to R&D: $2.9BOperating expenses to Sales, admin & other: $13.3B Medical Devices: $14.8B · 34% Medical Devices$14.8B34% Diagnostic Products: $16.5B · 38% Diagnostic Products$16.5B38% Nutritional Products: $7.5B · 17% Nutritional Products$7.5B17% Established Pharmaceutical Products: $4.9B · 11% Established Pharmaceuti…$4.9B11% Revenue: $43.7B Revenue$43.7B +1% Y/Y Gross profit: $24.5B · 56% margin Gross profit$24.5B56% margin Cost of revenue: $19.1B · 44% of revenue Cost of revenue$19.1B44% of revenue Operating profit: $8.4B · 19% margin Operating profit$8.4B19% margin −1% Y/Y Operating expenses: $16.1B · 37% of revenue Operating expenses$16.1B37% of revenue Net profit: $6.9B · 16% margin Net profit$6.9B16% margin −2% Y/Y Tax & other: $1.4B · 3% of revenue Tax & other$1.4B3% of revenue R&D: $2.9B · 7% of revenue R&D$2.9B7% of revenue Sales, admin & other: $13.3B · 30% of revenue Sales, admin & other$13.3B30% of revenue

Swipe sideways for the whole flow →

From $40.1B of sales to $5.7B of profit

FY2023, from the 10-K income statement and revenue by segment
Medical Devices to Revenue: $16.9BDiagnostic Products to Revenue: $10.0BNutritional Products to Revenue: $8.2BEstablished Pharmaceutical Products to Revenue: $5.1BRevenue to Gross profit: $22.1BRevenue to Cost of revenue: $18.0BGross profit to Operating profit: $6.5BGross profit to Operating expenses: $15.7BOperating profit to Net profit: $5.7BOperating profit to Tax & other: $755.0MOperating expenses to R&D: $2.7BOperating expenses to Sales, admin & other: $12.9B Medical Devices: $16.9B · 42% Medical Devices$16.9B42% Diagnostic Products: $10.0B · 25% Diagnostic Products$10.0B25% Nutritional Products: $8.2B · 20% Nutritional Products$8.2B20% Established Pharmaceutical Products: $5.1B · 13% Established Pharmaceuti…$5.1B13% Revenue: $40.1B Revenue$40.1B −8% Y/Y Gross profit: $22.1B · 55% margin Gross profit$22.1B55% margin Cost of revenue: $18.0B · 45% of revenue Cost of revenue$18.0B45% of revenue Operating profit: $6.5B · 16% margin Operating profit$6.5B16% margin −23% Y/Y Operating expenses: $15.7B · 39% of revenue Operating expenses$15.7B39% of revenue Net profit: $5.7B · 14% margin Net profit$5.7B14% margin −17% Y/Y Tax & other: $755.0M · 2% of revenue Tax & other$755.0M2% of revenue R&D: $2.7B · 7% of revenue R&D$2.7B7% of revenue Sales, admin & other: $12.9B · 32% of revenue Sales, admin & other$12.9B32% of revenue

Swipe sideways for the whole flow →

From $42.0B of sales to $13.4B of profit

FY2024, from the 10-K income statement and revenue by segment
Medical Devices to Revenue: $19.0BDiagnostic Products to Revenue: $9.3BNutritional Products to Revenue: $8.4BEstablished Pharmaceutical Products to Revenue: $5.2BRevenue to Gross profit: $23.2BRevenue to Cost of revenue: $18.7BGross profit to Operating profit: $6.8BGross profit to Operating expenses: $16.4BOperating profit to Net profit: $6.8BOther income to Net profit: $6.6BOperating expenses to R&D: $2.8BOperating expenses to Sales, admin & other: $13.6B Medical Devices: $19.0B · 45% Medical Devices$19.0B45% Diagnostic Products: $9.3B · 22% Diagnostic Products$9.3B22% Nutritional Products: $8.4B · 20% Nutritional Products$8.4B20% Established Pharmaceutical Products: $5.2B · 12% Established Pharmaceuti…$5.2B12% Revenue: $42.0B Revenue$42.0B +5% Y/Y Gross profit: $23.2B · 55% margin Gross profit$23.2B55% margin Cost of revenue: $18.7B · 45% of revenue Cost of revenue$18.7B45% of revenue Operating profit: $6.8B · 16% margin Operating profit$6.8B16% margin +5% Y/Y Other income: $6.6B · 16% of revenue Other income$6.6B16% of revenue Operating expenses: $16.4B · 39% of revenue Operating expenses$16.4B39% of revenue Net profit: $13.4B · 32% margin Net profit$13.4B32% margin +134% Y/Y R&D: $2.8B · 7% of revenue R&D$2.8B7% of revenue Sales, admin & other: $13.6B · 32% of revenue Sales, admin & other$13.6B32% of revenue

Swipe sideways for the whole flow →

From $44.3B of sales to $6.5B of profit

FY2025, from the 10-K income statement and revenue by segment
Medical Devices to Revenue: $21.4BDiagnostic Products to Revenue: $8.9BNutritional Products to Revenue: $8.5BEstablished Pharmaceutical Products to Revenue: $5.5BRevenue to Gross profit: $25.0BRevenue to Cost of revenue: $19.3BGross profit to Operating profit: $8.1BGross profit to Operating expenses: $17.0BOperating profit to Net profit: $6.5BOperating profit to Tax & other: $1.5BOperating expenses to R&D: $2.9BOperating expenses to Sales, admin & other: $14.0B Medical Devices: $21.4B · 48% Medical Devices$21.4B48% Diagnostic Products: $8.9B · 20% Diagnostic Products$8.9B20% Nutritional Products: $8.5B · 19% Nutritional Products$8.5B19% Established Pharmaceutical Products: $5.5B · 12% Established Pharmaceuti…$5.5B12% Revenue: $44.3B Revenue$44.3B +6% Y/Y Gross profit: $25.0B · 56% margin Gross profit$25.0B56% margin Cost of revenue: $19.3B · 44% of revenue Cost of revenue$19.3B44% of revenue Operating profit: $8.1B · 18% margin Operating profit$8.1B18% margin +18% Y/Y Operating expenses: $17.0B · 38% of revenue Operating expenses$17.0B38% of revenue Net profit: $6.5B · 15% margin Net profit$6.5B15% margin −51% Y/Y Tax & other: $1.5B · 3% of revenue Tax & other$1.5B3% of revenue R&D: $2.9B · 7% of revenue R&D$2.9B7% of revenue Sales, admin & other: $14.0B · 32% of revenue Sales, admin & other$14.0B32% of revenue

Swipe sideways for the whole flow →

Where each $100 of sales went

FY2021
FY2022
FY2023
FY2024
FY2025
  • Cost of revenue
  • R&D
  • Sales, admin & other
  • Tax, less other income
  • Net profit

Band widths are the money. Gross profit is revenue less cost of revenue; operating expenses are gross profit less operating profit; R&D is from the income statement and the rest of the operating expenses is everything else; tax includes interest and other items when they are small. Y/Y is the change from the fiscal year before. Revenue by part only for the years in the last two 10-Ks' segment tables. The full income statement →

Profitability

2 of 3
  • ✓
    Net margin above the peer median9.7% vs 9.6%
  • !
    Return on equity below 15%9.2%
  • ✓
    A profit in every one of 10 years
Net margin, FY2016 to FY2025: 6.7% → 14.7%

Balance sheet

3 of 4
  • ✓
    Interest covered more than 5 timesOperating income is 16.3× interest expense
  • ✓
    Debt smaller than equityDebt / equity 0.61 on the latest balance sheet (peer median 0.66)
  • ✓
    Current assets cover current liabilitiesCurrent ratio 1.45
  • !
    Net debt over 3 years of free cash flow$26.7B net debt, 3.9 years
Debt / equity at each year end, FY2016 to FY2025: 1.07 → 0.25
What the debt is made of ↓

Cash and shareholders

4 of 4
  • ✓
    Free cash flow positive in every one of 10 years$7.4B last year
  • ✓
    Share count down over 5 years−2.1%
  • ✓
    Dividend per share up over 3 years$1.92 → $2.40
  • ✓
    Cash from operations above net income$9.6B vs $6.5B
Free cash flow, FY2016 to FY2025: 2.1B → 7.4B

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

What the debt is made of, and when it is due

balance sheet of Sep 30, 2026 · schedule of Dec 31, 2025
Debt: $31.2B Debt$31.2B Long-term debt: $29.5B · 95% Long-term debt$29.5B · 95% Due within a year: $1.7B · 5% Due within a year$1.7B · 5% Next 12 months: $3.0B · 10% Next 12 months$3.0B · 10% Year 2: $700.0M · 2% Year 2$700.0M · 2% Year 3: $653.0M · 2% Year 3$653.0M · 2% Year 4: $591.0M · 2% Year 4$591.0M · 2% Year 5: $650.0M · 2% Year 5$650.0M · 2% After year 5: $7.4B · 24% After year 5$7.4B · 24%

The debt note's own lines, 2025-12-31

Fixed rate $0Floating $589.0M Not stated $12.4B

Line, as the company names itKindRateFixed or floatingAmount
4.90% Notes, due 2046Notes and bonds4.90%not stated$3.2B
3.75% Notes, due 2026Notes and bonds3.75%not stated$1.7B
4.75% Notes, due 2036Notes and bonds4.75%not stated$1.6B
1.50% Notes, due 2026Notes and bonds1.50%not stated$1.3B
4.75% Notes, due 2043Notes and bonds4.75%not stated$700.0M
0.375% Notes, due 2027Notes and bonds0.38%not stated$695.0M
5.30% Notes, due 2040Notes and bonds5.30%not stated$694.0M
1.15% Notes, due 2028Notes and bonds1.15%not stated$650.0M
1.40% Notes, due 2030Notes and bonds1.40%not stated$650.0M
5-year term loan due 2029Bank loans–floating$589.0M
6.15% Notes, due 2037Notes and bonds6.15%not stated$547.0M
6.00% Notes, due 2039Notes and bonds6.00%not stated$515.0M
All 12 lines

From the debt note in the 10-K's XBRL (0001628280-26-010185), as the company tags it: by issue, by year, by currency or by kind. Lines from two ways of cutting the same debt can overlap, so they are not added up. Fixed or floating is read from the line's own name only; "not stated" when it says neither.

Left: the debt lines on the balance sheet (XBRL). Right: the principal due each year, from the debt note's maturity schedule; it can differ a little from the balance sheet, which shows the debt net of discounts and fees. Leases are not counted. The full schedule →

Revenue and net income, FY2016 to FY2025

Revenue 44.3B Net income 6.5B
FY2016 revenue 20.9B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001047469-19-000624 FY2016 net income 1.4B · NetIncomeLoss, 0001047469-19-000624 20.9B FY2016 FY2017 revenue 27.4B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001104659-20-023904 FY2017 net income 477.0M · NetIncomeLoss, 0001104659-20-023904 27.4B FY2017 FY2018 revenue 30.6B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001104659-21-025751 FY2018 net income 2.4B · NetIncomeLoss, 0001104659-21-025751 30.6B FY2018 FY2019 revenue 31.9B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001104659-22-025141 FY2019 net income 3.7B · NetIncomeLoss, 0001104659-22-025141 31.9B FY2019 FY2020 revenue 34.6B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001628280-23-004026 FY2020 net income 4.5B · NetIncomeLoss, 0001628280-23-004026 34.6B FY2020 FY2021 revenue 43.1B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001628280-24-005348 FY2021 net income 7.1B · NetIncomeLoss, 0001628280-24-005348 43.1B FY2021 FY2022 revenue 43.7B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001628280-25-007110 FY2022 net income 6.9B · NetIncomeLoss, 0001628280-25-007110 43.7B FY2022 FY2023 revenue 40.1B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001628280-26-010185 FY2023 net income 5.7B · NetIncomeLoss, 0001628280-26-010185 40.1B FY2023 FY2024 revenue 42.0B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001628280-26-010185 FY2024 net income 13.4B · NetIncomeLoss, 0001628280-26-010185 42.0B FY2024 FY2025 revenue 44.3B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001628280-26-010185 FY2025 net income 6.5B · NetIncomeLoss, 0001628280-26-010185 44.3B FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. Full financials →

ABT's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Annual Quarterly
Revenue44.3B
FY2016: 20.9BFY2017: 27.4BFY2018: 30.6BFY2019: 31.9BFY2020: 34.6BFY2021: 43.1BFY2022: 43.7BFY2023: 40.1BFY2024: 42.0BFY2025: 44.3B FY2017FY2019FY2021FY2023FY2025
Net income6.5B
FY2016: 1.4BFY2017: 477.0MFY2018: 2.4BFY2019: 3.7BFY2020: 4.5BFY2021: 7.1BFY2022: 6.9BFY2023: 5.7BFY2024: 13.4BFY2025: 6.5B FY2017FY2019FY2021FY2023FY2025
Free cash flow7.4B
FY2016: 2.1BFY2017: 4.4BFY2018: 4.9BFY2019: 4.5BFY2020: 5.7BFY2021: 8.6BFY2022: 7.8BFY2023: 5.1BFY2024: 6.4BFY2025: 7.4B FY2017FY2019FY2021FY2023FY2025
EPS (diluted)3.72
FY2016: 0.94FY2017: 0.27FY2018: 1.33FY2019: 2.06FY2020: 2.50FY2021: 3.94FY2022: 3.91FY2023: 3.26FY2024: 7.64FY2025: 3.72 FY2017FY2019FY2021FY2023FY2025
Dividend per share2.40
FY2016: -FY2017: -FY2018: -FY2019: -FY2020: -FY2021: -FY2022: 1.92FY2023: 2.08FY2024: 2.24FY2025: 2.40 FY2017FY2019FY2021FY2023FY2025
Diluted shares1.7B
FY2016: 1.5BFY2017: 1.7BFY2018: 1.8BFY2019: 1.8BFY2020: 1.8BFY2021: 1.8BFY2022: 1.8BFY2023: 1.7BFY2024: 1.7BFY2025: 1.7B FY2017FY2019FY2021FY2023FY2025

Revenue by business segment

year to Dec 31, 2025
RevenueSharevs year before
Medical Devices 21.4B48.2% +12.6%
Diagnostic Products 8.9B20.2% -4.3%
Nutritional Products 8.5B19.1% +0.5%
Established Pharmaceutical Products 5.5B12.5% +6.6%

10-K 0001628280-26-010185, segment and revenue notes (XBRL).

Revenue by region

year to Dec 31, 2025
RevenueSharevs year before
Non-US 27.2B61.4% +6.1%
United States 17.1B38.6% +4.9%
All Other Countries 16.0B36.0% +8.1%
Germany 2.8B6.2% +8.7%
China 1.9B4.3% -9.7%
Switzerland 1.9B4.2% +7.1%
India 1.9B4.2% +3.0%
Japan 1.5B3.3% +2.4%
United Kingdom 1.3B3.0% +13.1%

10-K 0001628280-26-010185, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue20.9B27.4B30.6B31.9B34.6B43.1B43.7B40.1B42.0B44.3B
Cost of revenue9.1B12.4B12.7B13.2B15.0B18.5B19.1B18.0B18.7B19.3B
R&D1.4B2.3B2.3B2.4B2.4B2.7B2.9B2.7B2.8B2.9B
SG&A6.7B9.2B9.7B9.8B9.7B11.3B11.2B10.9B11.7B12.3B
Operating income3.0B1.6B3.6B4.5B5.4B8.4B8.4B6.5B6.8B8.1B
Interest expense431.0M904.0M826.0M670.0M546.0M533.0M558.0M637.0M559.0M493.0M
Pretax income1.4B2.2B2.9B4.1B5.0B8.2B8.3B6.7B7.0B8.5B
Income tax350.0M1.9B539.0M390.0M497.0M1.1B1.4B941.0M-6.4B1.9B
Net income1.4B477.0M2.4B3.7B4.5B7.1B6.9B5.7B13.4B6.5B
EPS (diluted)0.940.271.332.062.503.943.913.267.643.72
Diluted shares1.5B1.7B1.8B1.8B1.8B1.8B1.8B1.7B1.7B1.7B
Depreciation & amortization803.0M1.0B1.1B1.1B1.2B1.5B1.3B1.3B1.3B1.4B
EBITDA3.8B2.6B4.8B5.6B6.6B9.9B9.6B7.8B8.2B9.5B
Operating margin14.5%5.7%11.9%14.2%15.5%19.6%19.2%16.2%16.3%18.2%
Net margin6.7%1.7%7.7%11.6%13.0%16.4%15.9%14.3%31.9%14.7%
Revenue growth-+31.3%+11.6%+4.3%+8.5%+24.5%+1.3%-8.1%+4.6%+5.7%
EPS growth--71.3%+393%+54.9%+21.4%+57.6%-0.8%-16.6%+134%-51.3%

Balance sheet

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash18.6B9.4B3.8B3.9B6.8B9.8B9.9B6.9B7.6B8.5B
Short-term investments155.0M203.0M242.0M280.0M310.0M450.0M288.0M383.0M351.0M417.0M
Receivables3.2B5.2B5.2B5.4B6.4B6.5B6.2B6.6B6.9B7.9B
Inventory2.4B3.6B3.8B4.3B5.0B5.2B6.2B6.6B6.2B6.5B
Current assets26.8B20.1B14.6B15.7B20.4B24.2B25.2B22.7B23.7B26.0B
Property & equipment5.7B7.6B7.6B8.0B9.0B9.0B9.2B10.2B10.7B11.8B
Goodwill7.7B24.0B23.3B23.2B23.7B23.2B22.8B23.7B23.1B24.0B
Total assets52.7B76.2B67.2B67.9B72.5B75.2B74.4B73.2B81.4B86.7B
Current liabilities6.7B8.9B9.0B10.9B11.9B13.1B15.5B13.8B14.2B16.5B
Total debt22.0B27.9B19.6B18.1B18.7B18.1B16.8B14.7B14.1B12.9B
Shareholders' equity20.5B30.9B30.5B31.1B32.8B35.8B36.7B38.6B47.7B52.1B
Retained earnings25.6B24.0B24.6B25.8B27.6B31.5B35.3B37.6B47.3B49.8B

Cash flow

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow3.2B5.6B6.3B6.1B7.9B10.5B9.6B7.3B8.6B9.6B
Capital spending1.1B1.1B1.4B1.6B2.2B1.9B1.8B2.2B2.2B2.2B
Free cash flow2.1B4.4B4.9B4.5B5.7B8.6B7.8B5.1B6.4B7.4B
Stock-based pay (added back)310.0M406.0M477.0M519.0M546.0M640.0M685.0M644.0M673.0M664.0M
Dividends paid1.5B1.8B2.0B2.3B2.6B3.2B3.3B3.6B3.8B4.1B
Buybacks522.0M117.0M238.0M718.0M403.0M2.3B3.8B1.2B1.3B893.0M
Acquisitions80.0M17.2B--------
Debt raised14.9B6.7B4.0B1.8B1.3B4.0M----
Debt repaid12.0M8.7B12.4B3.4B1.3B48.0M----
Investing cash flow-248.0M-9.6B-1.4B-1.8B-2.2B-2.0B-1.7B-3.1B-2.3B-2.4B
Financing cash flow11.1B-5.3B-10.4B-4.3B-2.8B-5.5B-7.6B-7.1B-5.4B-6.3B
Dividend per share------1.922.082.242.40

Stock-based pay and leases

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)310.0M406.0M477.0M519.0M546.0M640.0M685.0M644.0M673.0M664.0M
Stock-based pay / revenue1.5%1.5%1.6%1.6%1.6%1.5%1.6%1.6%1.6%1.5%
Operating lease cost---314.0M329.0M359.0M355.0M356.0M366.0M391.0M
Operating lease cash paid---253.0M264.0M287.0M274.0M276.0M300.0M315.0M
Right-of-use assets---934.0M1.1B1.2B1.1B1.1B1.1B1.1B
Operating lease liabilities---960.0M1.1B1.2B1.2B1.2B1.1B1.2B

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Work on ABT in a spreadsheet: Excel workbook (a sheet per section, ten years by column, charts, links to the filings) · CSV. For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/ABT/export.csv") into a cell.